CommentClinical update: new treatments for age-related macular degeneration
References (18)
Intravitreal avastin: the low cost alternative to lucentis?
Am J Ophthalmol
(2006)- et al.
The epidemiology of age-related macular degeneration
Am J Ophthalmol
(2004) - et al.
Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans
Ophthalmology
(2007) - et al.
Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study
Ophthalmology
(2007) - et al.
Pegaptanib for neovascular age-related macular degeneration
N Engl J Med
(2004) Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration
Ophthalmology
(2007)- et al.
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Ranibizumab versus Verteporfin for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Evolving European guidance on the medical management of neovascular age related macular degeneration
Br J Ophthalmol
(2006)
Cited by (130)
Evaluation of YouTube videos as a patient information source on intravitreal injection procedures
2022, Journal Francais d'OphtalmologieClinical explainable differential diagnosis of polypoidal choroidal vasculopathy and age-related macular degeneration using deep learning
2022, Computers in Biology and MedicinePosterior cyclodialysis cleft following intravitreal injection
2021, American Journal of Ophthalmology Case ReportsCitation Excerpt :Intravitreal injections (IVIs) are among the most commonly performed ophthalmic procedures worldwide.1,2 Specifically, IVIs of anti-vascular endothelial growth factors are among mainstay treatments for complications of diabetic retinopathy, retinal vascular occlusions, and age-related macular degeneration.3–5 In general, IVIs are well-tolerated.
Trans-ocular Electric Current In Vivo Enhances AAV-Mediated Retinal Gene Transduction after Intravitreal Vector Administration
2019, Molecular Therapy Methods and Clinical DevelopmentCitation Excerpt :Intravitreal injection is favored over the subretinal vector administration because it is less invasive for vector delivery. Human clinical intravitreal injection of drugs is now quite common in using anti-VEGF compounds to treat neovascular complications of age-related macular degeneration43 and diabetic retinopathy.44 Currently, however, AAV delivery by intravitreal injection has limited capacity to transduce retinal cells, especially the RPE and photoreceptors.
Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy
2019, Canadian Journal of Ophthalmology